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Usefulness of serum cystatin C to determine the 
dose of vancomycin in neonate
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Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
Purpose: The vancomycin dosage regimen is regularly modified according to the patient’s glomerular 
filtration rate (GFR). In the present study, we aimed to assess the usefulness of serum cystatin C 
(Cys-C) concentration, compared with serum creatinine (SCr) concentration, for predicting vancomycin 
clearance (CLvcm) in neonates. 
Methods: We retrospectively analyzed the laboratory data of 50 term neonates who were admitted 
to the neonatal intensive care unit and received intravenous vancomycin, and assessed the 
pharmacokinetic profiles. Creatinine clearance (CLcr) and GFR based on Cys-C (GFRcys-c) were 
estimated using the Schwartz and Larsson formulas, respectively. 
Results: The mean CLvcm (±standard deviation) was 74.52±31.17 L/hr, the volume of distribution 
of vancomycin was 0.67±0.14 L, and vancomycin half-life was 9.16±17.42 hours. The SCr was 
0.46±0.25 mg/dL and serum Cys-C was 1.43±0.34 mg/L. The peak and trough concentrations of 
vancomycin were 24.65±14.84 and 8.10±5.35 mcg/mL, respectively. The calculated GFR based on 
serum creatinine concentration (GFR-Cr) and GFRcys-c were 70.2±9.45 and 63.6±30.18 mL/min, 
respectively. The correlation constant for CLvcm and the reciprocal of Cys-C (0.479, P=0.001) was 
significantly higher than that for CLvcm and the reciprocal of SCr (0.286, P=0.044). GFRcys-c was 
strongly correlated with CLvcm (P=0.001), and the correlation constant was significantly higher than 
that for CLvcm and CLcr (0.496, P=0.001). Linear regression analysis showed that only GFRcys-c was 
independently and positively correlated with CLvcm (F=41.9, P<0.001). 
Conclusion: The use of serum Cys-C as a marker of CLvcm could be beneficial for more reliable 
predictions of serum vancomycin concentrations, particularly in neonates. 
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Introduction
Vancomycin is glycopeptide antibiotics which is used to treat gram positive bacterial 
infection including methicillin-resistant Staphylococcus aureus (MRSA). In neonates, 
vancomycin is applied as an empirical antibiotics for those who have sepsis or line-related 
infection1). As vancomycin has narrow therapeutic range and the concentration-effect and 
concentration-toxicity of the drug is well established, it is recommended to apply 
therapeutic drug monitoring (TDM) in neonates2). 
Vancomycin is eliminated from the body primarily by the way of glomerular filtration 
rate (GFR)3). So, dosing of the vancomycin is mainly determined by renal function, especially 
GFR. Schwartz formula is widely used GFR in pediatric patients including neonates, using 
serum creatinine. However, using the serum creatinine (SCr) level as a GFR-determining 
factor has several limitations due to age, muscle mass, and hydration status4). Moreover, SCr 
levels are not altered until there is a loss of 25% to 50% of kidney function and in neonates. 
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Serum Cystatin C (Cys-C) is endogenous GFR marker which is 
independent of muscle mass. It is produced by a housekeeping 
gene expressed in all nucleated cells at a constant rate and is freely 
filtered at the glomerulus with no tubular secretion. Furthermore, 
Cys-C is completely catabolized by the renal tubules and its 
plasma level is only dependent on the GFR5). The production of 
Cys-C is not affected by inflammatory condition6). In normal 
kidney, Cys-C is not reabsorbed to blood flow after GFR. The 
reciprocal of Cys-C has proven to strongly correlate with GFR 
which is superior to SCr. Several meta-analyses have shown that 
Cys-C is superior to SCr for the estimation of the GFR in children7).
However, the estimation of renal function using serum Cys-C in 
neonate is still on research stage. Also, application of Cys-C to 
drug TDM in neonate is not tried yet. This research is the first trial 
of applying GFR based on serum Cys-C to predict vancomycin 
clearance (CLvcm) in Korean neonate. 
Materials and methods
1. Subjects
All data was collected at a Gangnam Severance Hospital neo-
natal intensive care unit from May 2008 to May 2013, retrospec-
tively. We included term neonate patients who received vanco-
mycin. Preterm infants, patients with congenital anomaly, and 
patients with liver or kidney disorder were excluded. Total patient 
number was 50 (35 males, 15 females) and their demographic 
characteristics and laboratory data are listed in Table 1. 
2. Vancomycin administration and sample collection
Vancomycin (10 mg/kg to 15 mg/kg of single dose) was admini-
strated via intravenous infusion over 60 minutes with a dosage 
interval of 8 to 12 hours according to postmenstrual age of the pa-
tients. The blood sampling time of peak and trough van comycin 
concentration were right before vancomycin infusion and 1 hour 
after the end of vancomycin infusion. All blood samples were 
collected in a steady state. Serum sample for Cys-C and SCr was 
drawn at one of the vancomycin sampling time. Other laboratory 
results including serum blood urea nitrogen, aspartate amino-
transferase (AST), alanine aminotransferase (ALT), albumin, C- 
reactive protein were also obtained.      
3. Laboratory analysis methods
Serum concentrations of vancomycin were analyzed by fluo-
rescence polarization immunoassay methods (Abbott TDx analy-
zer, Abbott Laboratories, Abbott Park, IL, USA). This method has a 
coefficient of variation of less than 6% for between-day as well as 
within-run imprecision. The lower limit of detection was 2.0 μg/
mL. SCr concentrations were measured by an enzymatic method (a 
kinetic picrate method in an alkaline medium in an Advia 1650 
analyzer [Bayer HealthCare Ltd., Tarrytown, NY, USA]; OutoL 
MIZUHO CRE (N); [Mizuho Co., Saga, Japan]) using an auto-
analyzer (HITACHI 7600, Hitachi Co., Tokyo, Japan). This method 
has a coefficient of variation of less than 3.0%, and the range of 
measurement is 0 to 100 mg/dL. Serum concentrations of Cys-C 
were determined using Latex immuno-turbidimetric assay using 
IatroCys-C (Mitsubishi Kagaku Iatron Co., Tokyo, Japan) with an 
auto-analyzer (HITACHI 7170, Hitachi Co., Tokyo, Japan). This 
method has a coefficient of variation of less than 10% in the range 
of 0.1 to 8.0 mg/L. Reference range of Cys-C were 0.65–1.10 mg/L 
for term neonates. Serum albumin concentration and the activities 
of AST, ALT, and alkaline phosphatase were determined in an 
Advia 1650 analyzer.
The predicted creatinine clearance (CLcr) was calculated ac-
cording to the Schwartz formula using the height of the patients, 
and the results were normalized to a body surface area of 1.73 m2. 
The predicted values of GFR derived from serum Cys-C concen-
trations were calculated according to the expression proposed by 
Larsson et al.8): GFR (mL/min)=99.43×(serum Cys-C)–1.5837, and the 
results were normalized to a body surface area of 1.73 m2. 
4. Pharmacokinetics analysis and evaluation of renal function
The pharmacokinetic analysis was carried out using the Abbott 
base Pharmacokinetics Systems program from Abbott Laboratories 
using a Bayesian model. The model considered for vancomycin 
was a linear 2-compartment model, and the population pharma-
cokinetic parameters used were: volume of distribution= 0.21±0.04 
L/kg; clearance (CL)=0.05±0.01 mL/min/kg; CL renal (slope)=0.75 
±0.25; rate constant for distribution from central to peripheral 
Table 1. Demographic characteristics and biochemical parameters of 
patients
Variable Value
No. of patients 50
Sex
Male:female 35:15
NSVD/C-sec 11/39
Gestational age (wk) 39.40±0.94
Birth weight (kg) 3.20±0.35
Age at examination (day) 19.12±15.55
Body weight at examination (kg) 3.54±0.46
Length at examination (cm) 50.21±3.53
Blood urea nitrogen (mg/dL) 12.38±11.81
AST (IU/L) 42.6±40.12
ALT (IU/L) 24.8±24.56
Albumin (g/dL) 3.38±0.57
C-reactive protein (mg/L) 25.3±40.41
Values are presented as numbers or mean±standard deviation.
NSVD, normal spontaneous vaginal delivery; C-sec, cesarean section; AST, 
aspartate transaminase; ALT, alanine aminotransferase. 
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compartment (K12)=1.12±0.28/hr; Rate constant for distribution 
from peripheral to central compartment (K21)=0.48±0.12/hr. In all 
the cases, the estimations of the pharmacokinetic parameters, peak 
concentration, CL, and half-life (t1/2) were carried out by entering 
the creatinine clearance predicted by the serum creatinine con-
centration and the GFR predicted by the serum concentration of 
Cys-C as GFR value into the programming.
CLcr (mL/min) was estimated using the Schwartz formula9) as 
follows:
CLcr (mL/min)=k × height/SCr (k=0.45 in term neonate)  
GFRcys-c (mL/min) was estimated using Larsson’s formula8) as 
follows:
GFRcys-c (mL/min)=99.43 × [serum Cys-C (mg/L)]–1.5837
5. Statistical analysis
Data are presented as the mean±standard deviation. The rela-
tionship between CLvcm and parameters of renal function (Cys-C, 
SCr, GFRcys-c, CLcr) was assessed by correlation analysis and 
linear regression using Spearman’s correlation coefficient. IBM 
SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA) was used. A 
P value of <0.05 was considered to be significant.  
Results
The mean gestational age was 39.40±0.94 weeks and the mean 
birth weight was 3.20±0.35 kg. The mean age at examination was 
19.12±15.45 days from birth. The mean serum Cys-C level and 
creatinine level were 1.44±0.34 mg/L and 0.46±0.25 mg/L. Other 
laboratory results showed no remarkable findings. The volume of 
distribution of vancomycin was 0.67±0.13 L/kg and CLvcm was 
74.52±31.17 mL/kg/hr. SCr showed 0.46±0.25 mg/dL, and serum 
Cys-C showed 1.44±0.34 mg/L. Peak and trough concentration of 
vancomycin showed 24.65±14.84 mcg/mL and 8.10±5.35 mcg/
mL. Calculated GFR-Cr and GFRcys-C were 70.32±9.45 mL/min 
and 63.63±30.18 mL/min (Tables 1, 2).
The reciprocal of cystatin C (1/Cys-C) was correlated well with 
CLvcm (c=0.479, P=0.001) and the reciprocal of serum creatinine 
(1/SCr) was also correlated with CLvcm (c=0.286, P=0.044). To 
conclude, the correlation constant of CLvcm and 1/Cys-C was 
significantly higher than that CLvcm and 1/Cr. GFRcys-c was 
strongly correlated with CLvcm (P=0.001) and the constant was 
0.496. GFRcr also had significant correlation with CLvcm (c= 
0.527, P=0.036) (Fig. 1).
However, linear regression analysis showed that only GFRcys-c 
were independently positively correlated with CLvcm (F=41.9, 
P<0.001) (Table 3). None of the patients showed nephrotoxicity of 
vancomycin; decreased urination or increased serum creatinine 
after the drug administration.   
Discussion
So far, there has been no report that serum Cys-C concentration 
is useful for adjusting the dose of vancomycin in Korean neonate 
population. This study showed the use of serum Cys-C as a marker 
of vancomycin clearance had more reliable predictions of serum 
vancomycin concentrations than the use of SCr particularly 
among neonates.
Vancomycin, a glycopeptide antibiotics, has been used effec-
tively against aerobic gram positive, especially MRSA infections. 
However, due to elimination via kidney, vancomycin has the 
potential to cause severe nephrotoxic adverse reactions. Especially 
in neonates, the renal function is quite different from that of adults 
and older children. Despite a rapid decrease after birth in normal 
newborns, SCr is frequently higher than 90 mol/L during the first 
days of life10). An appropriate dose and dosage intervals must be 
chosen to achieve the maximal effect and to avoid toxicity 
according to the degree of renal function. 
The pharmacokinetics of vancomycin in neonates is different 
from that in adults because of the variation in the amount of body 
water and maturation of renal function. Neonates have a larger 
volume of distribution and decreased total clearance, and that 
results in wider interindividual differences in neonates than in 
adults11). From our study, the peak concentration of vancomycin 
was 24.66±14.84 mcg/mL and the trough concentration was 
8.10±5.35 mcg/mL. The volume of distribution was 0.67±0.13 L/
kg. Reported average volume of distribution at steady state in term 
neonates ranges from 0.57 to 0.69 L/kg which is larger than that 
of adults3). Nephrotoxocity has been related to trough concentra-
tion >10 mg/L, but in most studies, it remains unclear whether 
elevated serum trough concentration are the cause or consequence 
of renal failure12,13). Although many studies could not detect 
nephrotoxicity, there are some reports of vancomycin-related 
nephrotoxicity in neonates. Leonard et al.14) reported that three out 
of 12 very low birth weight infants treated with vancomycin had a 
Table 2. Pharmacokinetic analysis
Variable Mean±SD Range
Creatinine (mg/L) 0.46±0.25 0.17–1.37
Cystatin C (mg/L) 1.44±0.34 0.65–2.49
Volume of distribution (L/kg) 0.67±0.13 0.25–0.90
Clearance (mL/hr/kg) 74.52±31.17 4.2–173.4
Half-life (hr) 9.16±17.43 2.7–129
Peak concentration (mcg/mL) 24.65±14.84 2.9–72.2
Trough concentration (mcg/mL) 8.10±5.35 0.9–31.3
GFR-Cr (mL/min/1.73 m2) 70.32±9.45 17.74–129.71
GFR-CysC (mL/min/1.73 m2) 63.63±30.18 23.44–196.70
SD, standard deviation; GFR, glomerular filtration rate; Cr, creatinine; CysC, 
cystatin C. 
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utilized to estimate the GFR are the SCr concentration, the CLcr. 
However, CLcr may be less accurate in some individuals with 
children, and those with unusual muscle mass, body habitus, and 
weight. Cys-C, a low molecular weight protein is filtered at the 
glomerulus and not reabsorbed. The rate of production has been 
thought to be relatively constant, and not affected by changes in 
diet, gender, age or muscle mass14,15). The serum Cys-C concen-
tration may correlate more closely with the GFR than the SCr 
concentration16-20). In multiple studies, serum Cys-C was more 
sensitive in identifying mild renal insufficiency than SCr17,20). Using 
the clearance of radioactive iothalamate as the gold stan dard, 
serum Cys-C levels began increasing at GFR levels of approxi-
mately 90 mL/min per 1.73 m2, while the SCr only in creased when 
the GFR was approximately 70 mL/min per 1.73 m2. Meta-analysis 
of recent studies suggests that serum Cys-C may be a better marker 
for GFR estimation than SCr21). A report for a population phar-
rise of SCr of more than 0.3 mg/dL. Therefore, it is imperative to 
apply TDM to neonates treated with vancomycin. 
Direct techniques for evaluating GFR, which involve inulin or 
radiopharmaceuticals, are expensive and impractical in clinical 
work or for screening large populations. The most common method 
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Fig. 1. Correlation analysis between CLvcm and 1/SCr, 1/Cys-C, GFRcys-c, and GFR-Cr. CLvcm, vancomycin clearance; SCr, 
serum creatinine; Cys-C, serum cystatin C concentration; GFR, glomerular filtration rate; GFRcys-c, GFR based on Cys-C; GFR-
Cr, GFR based on serum creatinine concentration.
Table 3. Linear regression analysis of vancomycin clearance  
Variable Beta P value
GFR-CysC 0.907 <0.001
GFR-Cr –0.112 0.510
Peak concentration 0.017 0.927
Through concentration –0.097 0.607
Half-life –0.171 0.376
Volume of distribution 0.104 0.492
Cr, creatinine; CysC, cystatin C. 
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macokinetic model of vancomycin using NONMEM software (Icon 
Development Solutions, Ellicott City, MD, USA) from a total of 
1,373 vancomycin concentration measurements in 678 Korean 
patients whose serum creatinine concentrations were lower than 
1.2 mg/dL were noted. A population pharmacokinetic model of 
vancomycin was revealed that Cys-C was the most influential 
factor and had negative influence (–0.78) in the relationship. Total 
body weight, sex, age, and serum creatinine were also significantly 
correlated with the clearance. A 14-fold difference in predicted 
trough concentrations was observed according to only Cys-C 
concentrations22). Several studies including adults and children 
with different renal diseases with various kidney function have 
suggested serum Cys-C to be a better marker of GFR than SCr23). 
One TDM study pointed out the risk of overestimation of GFR 
when using SCr, and suggested Cys-C as a valid alternative as a 
GFR marker with regard to drug dose adjustment for vancomycin 
and amikin24). Okamoto et al.4) reported higher correlation for 
CLvcm and the GFRcys-c compared to that for CLvcm and CLcr 
with smaller coefficient of variation, which suggests that Cys-C as 
a more reliable marker for predicting CLvcm in elderly patients 
treated with vancomcyin. 
The major limitation of this study is a single center study and 
small sample size. Furthermore, the effective range of vancomycin 
in neonates has not yet been determined. Because of the use of 
vague standards to determine efficacy, we could not assess whe-
ther the desired therapeutic effects were achieved. Further research 
with a larger study population and longer follow-up is necessary.
We investigated the utility of serum Cys-C concentration for 
predicting CLvcm compared with SCr as a marker of the renal 
function. So far, no study has investigated the direct relationship 
between CLvcm and GFR estimated based on Cys-C in neonates. 
To conclude, the present study suggests that the use of serum 
Cys-C as a marker of CLvcm is reliable and we expect this result 
would be useful particularly among neonates. 
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